Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: Regional Partnership Program : Manitoba

University of Manitoba

$100,000.00

Plant sterols and cholesterol: Assessment of sterol metabolism in heterozygous and homozygous sitosterolemia

EF 2011-12

Résumé
Cardiovascular disease is the leading cause of death in Canada. High blood cholesterol is a risk factor for cardiovascular diseases. Studies have shown that daily intake of plant sterols or ezetimibe can lower blood cholesterol concentrations. It is unknown whether plant sterols and ezetimibe have different mechanisms of action on cholesterol metabolism. Studying individuals with rare diseases such as sitosterolemia provides important insights into the mechanisms underlying cardiovascular disease risks. Sitosterolemia is a genetic disease caused by a defect in the genes that code for the proteins that normally carry plant sterol out of the body. Homozygous sitosterolemia is characterized by high accumulation of blood cholesterol and plant sterol levels which can lead to atherosclerosis at an early age and high risk for heart attack. The current treatment of choice for homozygous sitosterolemia is the drug ezetimibe. Compared to individuals with homozygous sitosterolemia, people with heterozygous sitosterolemia are not clinically sick but may have increased blood cholesterol concentration. Studies in people with homozygous and heterozygous sitosterolemia will help us to better understand how plant sterols affect cholesterol function in the body to reduce cardiovascular disease risk. The main goals of this research are, therefore, to study the effects of plant sterols intake on blood plant sterol and cholesterol concentration and metabolism in individuals with heterozygous sitosterolemia compared to non-carriers; and study the effects of ezetimibe treatment on plant sterols and cholesterol metabolisms in patients with homozygous sitosterolemia. This study will have important relevance to the health and wellness of Canadians by contributing to an improved understanding of the underlying mechanisms regulating cardiovascular disease development as well as identification of some genetic traits that correlate to various aspects of cholesterol metabolism.
Programme
Operating Grant - PA: Regional Partnership Program : Manitoba
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
249309
Name
Jones Peter J
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Manitoba Health Research Council
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Nutrition, Food & Health
Projecttitle
Plant sterols and cholesterol: Assessment of sterol metabolism in heterozygous and homozygous sitosterolemia
Programtype2
Operating Grants
Orgnameinp2
University of Manitoba
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Regional Partnership Program : Manitoba
Keyworddelim
Abcg8/G5; Cholesterol; Plant Sterols; Sitosterolemia; Stable Isotope
Abstract
Cardiovascular disease is the leading cause of death in Canada. High blood cholesterol is a risk factor for cardiovascular diseases. Studies have shown that daily intake of plant sterols or ezetimibe can lower blood cholesterol concentrations. It is unknown whether plant sterols and ezetimibe have different mechanisms of action on cholesterol metabolism. Studying individuals with rare diseases such as sitosterolemia provides important insights into the mechanisms underlying cardiovascular disease risks. Sitosterolemia is a genetic disease caused by a defect in the genes that code for the proteins that normally carry plant sterol out of the body. Homozygous sitosterolemia is characterized by high accumulation of blood cholesterol and plant sterol levels which can lead to atherosclerosis at an early age and high risk for heart attack. The current treatment of choice for homozygous sitosterolemia is the drug ezetimibe. Compared to individuals with homozygous sitosterolemia, people with heterozygous sitosterolemia are not clinically sick but may have increased blood cholesterol concentration. Studies in people with homozygous and heterozygous sitosterolemia will help us to better understand how plant sterols affect cholesterol function in the body to reduce cardiovascular disease risk. The main goals of this research are, therefore, to study the effects of plant sterols intake on blood plant sterol and cholesterol concentration and metabolism in individuals with heterozygous sitosterolemia compared to non-carriers; and study the effects of ezetimibe treatment on plant sterols and cholesterol metabolisms in patients with homozygous sitosterolemia. This study will have important relevance to the health and wellness of Canadians by contributing to an improved understanding of the underlying mechanisms regulating cardiovascular disease development as well as identification of some genetic traits that correlate to various aspects of cholesterol metabolism.
Competitiondate
201109
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Jones, Peter J
Approvedterm
2 ans 0 mois
Cihrcontribution2
SPIR~ $100,000~ $0~